Aura Biosciences, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Aura Biosciences, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($26.13M) | Nov 13, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($27.02M) | Aug 13, 2025 |
| Q3 | 2025 | Jun 30, 2025 | ($27.02M) | Nov 13, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($27.48M) | May 15, 2025 |
| Q3 | 2025 | Mar 31, 2025 | ($27.48M) | Nov 13, 2025 |
| Q2 | 2025 | Mar 31, 2025 | ($27.48M) | Aug 13, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($21.04M) | Nov 13, 2025 |
| Q3 | 2025 | Jun 30, 2024 | ($20.34M) | Nov 13, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($20.34M) | Aug 13, 2025 |
| Q2 | 2025 | Mar 31, 2024 | ($19.71M) | Aug 13, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($19.71M) | May 15, 2025 |
| Q3 | 2025 | Mar 31, 2024 | ($19.71M) | Nov 13, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($18.51M) | Nov 12, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($18.30M) | Aug 8, 2024 |
| Q3 | 2024 | Jun 30, 2023 | ($18.30M) | Nov 12, 2024 |
| Q3 | 2024 | Mar 31, 2023 | ($17.47M) | Nov 12, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($17.47M) | May 9, 2024 |
| Q2 | 2024 | Mar 31, 2023 | ($17.47M) | Aug 8, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($15.90M) | Nov 9, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($13.47M) | Aug 9, 2023 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($27.91M) | Nov 13, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($28.61M) | Aug 13, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($29.04M) | May 15, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($23.23M) | Nov 13, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($22.76M) | Aug 13, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($22.31M) | May 15, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($20.49M) | Nov 12, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($20.28M) | Aug 8, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($19.44M) | May 9, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($16.06M) | Nov 9, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($13.82M) | Aug 9, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($12.81M) | May 11, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($8.90M) | Nov 10, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($8.80M) | Aug 11, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($5.93M) | May 12, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($3.63M) | Nov 24, 2021 |